Skip to main content
Clinical Trials/NCT04743375
NCT04743375
Unknown
Not Applicable

Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment

Chulalongkorn University1 site in 1 country30 target enrollmentStarted: February 2021Last updated:

Overview

Phase
Not Applicable
Enrollment
30
Locations
1
Primary Endpoint
Time to complete healing

Overview

Brief Summary

To examine the efficacy and safety of sericin dressing with collagen in STSG donor site treatment comparing with Bactigras®. Around 30 patients will be enrolled in this study.

Detailed Description

Wounds are a public health problem found worldwide that associated with both clinical and economic burdens. Although several wound dressings are available, some limitations of those dressings still existed resulting in the need for new wound dressing development.

The sericin dressing with collagen was developed to provide a moist environment and bioactive ingredients to the wound bed. To evaluate its efficacy and safety, the STSG donor sites of each patient will be divided into two equal areas. Each area will be randomly allocated into sericin dressing with collagen group or control group (Bactigras®). The outcomes will be collected to examine the efficacy and safety of sericin dressing with collagen in comparison with commercial dressing Bactigras®.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients who have STSG donor site wounds on the thigh area
  • Age more than 18 years old
  • The split-thickness skin graft is harvested for the first time at the investigated area.
  • Patients who are able to communicate with the Thai language
  • Willingness to participate

Exclusion Criteria

  • Patient with a mental disorder or immunocompromised diseases
  • Patients who cannot or not willing to follow the protocol
  • Known sensitivity or allergy to sericin, chlorhexidine, and collagen
  • Pregnancy or lactation

Outcomes

Primary Outcomes

Time to complete healing

Time Frame: 42 days

The number of days since starting treatment until the primary dressing can spontaneously detach from wound with full re-epithelialization (at least 95% re-epithelialization) without any drainage.

Secondary Outcomes

  • Incidence of infection(42 days)
  • Incidence of adverse effect(42 days)
  • Pain score(42 days)
  • Vancouver scar scale (VSS)(6 months)
  • Patient scale of Patient and observer scar scale (POSAS)(6 months)
  • Melanin level(6 months)
  • Trans-epidermal water loss (TEWL)(6 months)
  • Skin hydration(6 months)
  • Erythema level(6 months)
  • Skin elasticity(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Pornanong Aramwit, Pharm.D., Ph.D

Professor

Chulalongkorn University

Study Sites (1)

Loading locations...

Similar Trials